Liu Bingcheng相关文献与解析，生知库 | 链接生命科学的每一步

Yuan, Mengyao; Zhou, Li; Li, Weiming; Du, Xin; Weng, Jianyu; Yang, Linhua; Ma, Yanping; Liu, Bingcheng; Liu, Zhenfang; Wen, Qin; Zhao, Shasha; Zhang, Yanli; Bai, Qingxian; Feng, Xianqi; Han, Yanqiu; Liu, Chunshui; Meng, Li; Wang, Baohong; Ran, Xuehong; Wang, Xiaodong; Zhang, Haiguo; Zeng, Yun; Leng, Qing; Yu, Lu; Li, Zongru; Gale, Robert Peter; Huang, Xiaojun; Jiang, Qian

白血病

细胞生物学

粒细胞

发表日期：2026

文献求助收藏

Impact of Fusion Partners and Transplantation Benefit in Intensively Treated KMT2A-Rearranged Acute Myeloid Leukemia

融合伴侣和移植获益对接受强化治疗的KMT2A重排急性髓系白血病的影响

期刊:Cancers

影响因子:4.4

doi:10.3390/cancers18030401

Shen, Heng; Chen, Jiayuan; Gong, Xiaoyuan; Zhou, Chunlin; Lin, Dong; Liu, Kaiqi; Gong, Benfa; Zhang, Guangji; Li, Yan; Liu, Yuntao; Qiu, Shaowei; Liu, Bingcheng; Wang, Ying; Mi, Yingchang; Fang, Qiuyun; Wang, Jianxiang; Wei, Hui

Dynamin2 mutations in newly diagnosed acute myeloid leukemia: clinical characteristics, and prognostic significance

新诊断急性髓系白血病中动力蛋白2突变：临床特征和预后意义

期刊:Experimental Hematology & Oncology

影响因子:13.5

doi:10.1186/s40164-025-00628-5

Luo, Kunpeng; Chen, Jiayuan; Wang, Wenting; Hui, Yan; Qiu, Shaowei; Liu, Bingcheng; Mi, Yingchang; Wang, Jianxiang; Wei, Hui

白血病

发表日期：2025

文献求助收藏

Clinical characteristics and therapeutic determinants of RUNX1::RUNX1T1 differ from those of CBFB::MYH11 acute myeloid leukemia

RUNX1::RUNX1T1 的临床特征和治疗决定因素与 CBFB::MYH11 急性髓系白血病不同。

期刊:Haematologica

影响因子:7.9

doi:10.3324/haematol.2024.287293

Yang, Miao; Wang, Wenting; Zhang, Guangji; Qiu, Shaowei; Liu, Bingcheng; Mi, Yingchang; Wang, Ying; Wang, Jianxiang; Wei, Hui

Measurable residual disease recurrence as early warning of relapse in acute myeloid leukemia

可测量的残留病灶复发可作为急性髓系白血病复发的早期预警信号

期刊:Haematologica

影响因子:7.9

doi:10.3324/haematol.2024.287119

Gong, Benfa; Yang, Miao; Qiu, Shaowei; Liu, Bingcheng; Wang, Ying; Mi, Yingchang; Wei, Hui; Wang, Jianxiang

Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia

优化慢性期慢性粒细胞白血病中奥维瑞巴替尼的剂量

期刊:Haematologica

影响因子:7.9

doi:10.3324/haematol.2024.287116

Zhang, Xiaoshuai; Yang, Yunfan; Liu, Bingcheng; Du, Xin; Wang, Xiaodong; Zhu, Huanling; Yu, Lu; Li, Zongru; Zhao, Shasha; Yang, Linhua; Ma, Yanping; Meng, Li; Zhang, Yanqing; Li, Guohui; Yang, Lijie; Wang, Baohong; Ran, Xuehong; Huang, Jian; Gao, Na; Wen, Qin; Wen, Yan; Zhao, Yuxia; Zhu, Yu; Han, Yanqiu; Liu, Zhenfang; Du, Xin; Weng, Jianyu; Gale, Robert Peter; Zhou, Li; Zhang, Yanli; Jiang, Qian

Progression significance for low-level aberrant B-lymphoblasts in chronic myeloid leukaemia patients

慢性粒细胞白血病患者中低水平异常B淋巴母细胞的进展意义

期刊:Clinical and Translational Medicine

影响因子:6.8

doi:10.1002/ctm2.70524

Wang, Haoren; Wang, Huijun; Li, Yuanyuan; Zheng, Bin; Fang, Qiuyun; Li, Yan; Liu, Yuntao; Gu, Runxia; Wang, Ying; Mi, Yingchang; Liu, Bingcheng; Wei, Hui; Wang, Jianxiang

KMT2C/D mutations in newly diagnosed acute myeloid leukaemia: Clinical features, genetic co-occurrences and prognostic significance

新诊断急性髓系白血病中KMT2C/D突变：临床特征、基因共现及预后意义

期刊:Clinical and Translational Medicine

影响因子:6.8

doi:10.1002/ctm2.70284

Wang, Wenting; Yang, Miao; Zhang, Xue; Chen, Jiayuan; Qiu, Shaowei; Liu, Bingcheng; Mi, Yingchang; Wang, Jianxiang; Wei, Hui

白血病

发表日期：2025

文献求助收藏

Patient-reported outcomes in adults with tyrosine kinase inhibitor-resistant chronic myeloid leukemia receiving olverembatinib therapy

接受奥维瑞巴替尼治疗的酪氨酸激酶抑制剂耐药性慢性粒细胞白血病成年患者的患者报告结局

期刊:Cancer

影响因子:5.1

doi:10.1002/cncr.35652

Yu, Lu; Li, Weiming; Xu, Na; Liu, Xiaoli; Liu, Bingcheng; Zhang, Yanli; Meng, Li; Zhu, Huanling; Du, Xin; Chen, Suning; Hu, Yu; Song, Yongping; Men, Lichuang; Jiang, Qian

Secondary malignancies after chronic myeloid leukaemia upon TKI treatment: Population trends and outcomes

慢性粒细胞白血病接受酪氨酸激酶抑制剂（TKI）治疗后继发性恶性肿瘤：人群趋势和预后

期刊:British Journal of Haematology

影响因子:3.8

doi:10.1111/bjh.20226

Zu, Yingling; Yue, Xipeng; Zhan, Xinrong; Liu, Xiaojuan; Ma, Hongxia; Qin, Fuli; Duan, Lijuan; Zhao, Hongmian; Zhang, Yan; He, Shiqiang; Zhao, Huifang; Zhang, Chunlei; Xin, Xiangke; Zhang, Wenli; Song, Yongping; Liu, Bingcheng; Li, Weiming; Zhang, Yanli

Olverembatinib in accelerated-phase chronic myeloid leukemia: efficacy and safety evaluation

Olverembatinib治疗加速期慢性粒细胞白血病：疗效和安全性评价

Impact of Fusion Partners and Transplantation Benefit in Intensively Treated KMT2A-Rearranged Acute Myeloid Leukemia

融合伴侣和移植获益对接受强化治疗的KMT2A重排急性髓系白血病的影响

Dynamin2 mutations in newly diagnosed acute myeloid leukemia: clinical characteristics, and prognostic significance

新诊断急性髓系白血病中动力蛋白2突变：临床特征和预后意义

Clinical characteristics and therapeutic determinants of RUNX1::RUNX1T1 differ from those of CBFB::MYH11 acute myeloid leukemia

RUNX1::RUNX1T1 的临床特征和治疗决定因素与 CBFB::MYH11 急性髓系白血病不同。

Measurable residual disease recurrence as early warning of relapse in acute myeloid leukemia

可测量的残留病灶复发可作为急性髓系白血病复发的早期预警信号

Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia

优化慢性期慢性粒细胞白血病中奥维瑞巴替尼的剂量

Progression significance for low-level aberrant B-lymphoblasts in chronic myeloid leukaemia patients

慢性粒细胞白血病患者中低水平异常B淋巴母细胞的进展意义

KMT2C/D mutations in newly diagnosed acute myeloid leukaemia: Clinical features, genetic co-occurrences and prognostic significance

新诊断急性髓系白血病中KMT2C/D突变：临床特征、基因共现及预后意义

Patient-reported outcomes in adults with tyrosine kinase inhibitor-resistant chronic myeloid leukemia receiving olverembatinib therapy

接受奥维瑞巴替尼治疗的酪氨酸激酶抑制剂耐药性慢性粒细胞白血病成年患者的患者报告结局

Secondary malignancies after chronic myeloid leukaemia upon TKI treatment: Population trends and outcomes

慢性粒细胞白血病接受酪氨酸激酶抑制剂（TKI）治疗后继发性恶性肿瘤：人群趋势和预后